Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:21 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
NCT02608268 · Novartis Pharmaceuticals · PHASE1/PHASE2 · terminated · last registry update 2023-12-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Business reasons” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HAVCR2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-06-11Results posted on the registry: Novartis Pharmaceuticals, sabatolimab + azacitidine (NCT04812548)
- 2024-04-11Also stopped (withdrawn): Novartis Pharmaceuticals, Sabatolimab + Magrolimab (NCT05367401)
- 2023-07-07Results posted on the registry: Novartis Pharmaceuticals, MBG453 + Placebo (NCT03946670)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision